Research & Development
Intravacc's inactivated polio vaccine awarded MNPA's market authorisation in China
20 July 2021 -

Netherlands' vaccines company Intravacc reported on Monday the receipt of approval from the Chinese National Medical Products Administration (NMPA) for the market authorisation of its Sabin-IPV (sIPV) inactivated polio vaccine in China in the ongoing efforts towards global polio eradication as well as reduce the vaccine-associated paralytic polio (VAPP) caused by oral polio vaccines (OPV).

The Sabin-IPV (sIPV) is an inactivated polio vaccine, developed by Intravacc and out-licensed to Sinovac, which expects to deliver the first Eupolio vaccines for the immunization of infants in 2021.

This multivalent polio vaccine was developed by Intravacc for the purpose of providing low and middle-income countries with the opportunity to produce their own safe polio vaccine in the context of the global polio eradication initiative.

This vaccine technology developed by Intravacc and transferred to Sinovac was also used for the development of "CoronaVac" Sinovac's inactivated Covid-19 vaccine validated by the WHO for emergence use and over 430m doses have already been administrated globally.

A rolling review is a regulatory tool that EMA uses to speed up the assessment of a promising medicine during a public health emergency. In that case EMA's human medicines committee (CHMP) reviews data as they become available from ongoing studies, concluded the company.



Related Headlines